NCT00783432View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

862

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Chronic Allergic RhinitisNonallergic Rhinitis
Interventions
DRUG

Astepro Nasal Spray (0.1% azelastine hydrochloride)

548 mcg (2 sprays per nostril) twice a day

DRUG

Astelin Nasal Spray (0.1% azelastine hydrochloride)

548 mcg (2 sprays per nostril) twice a day

Trial Locations (1)

08873

Meda Clinical Trials Contact Center, Somerset

Sponsors
All Listed Sponsors
lead

Meda Pharmaceuticals

INDUSTRY